Thyrocare TechnologiesQ2 FY24

Thyrocare Technologies Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹506.95P/E: 46.1Market Cap: ₹8.1K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • Franchise business revenue grew about 20% YoY with 8% volume growth; remaining growth driven by price mix (Rahul Guha, Page 17).
  • Price hikes were marginal at 4-5%, major growth achieved through mix of larger Aarogyam packages, Jaanch test menu, vitamins, etc.
  • Jaanch brand (diagnostic packages) reached ₹1 crore per month within 3 months and targets ₹25-30 crores revenue next year (Page 13).
  • Hospital channel expansion is slow with only 2-3 hospitals currently, business still learning and not material yet (Page 14).
  • Nuclear business expected to reach profitability with ₹12-12.5 crores quarterly revenue by H1 FY 2025 (Page 10).
  • Overall 10% consolidated revenue growth YoY (Page 5) with franchise business strong and partnership business growing excluding API and B2G.
  • Operating leverage likely to start kicking in FY 2025 with EBITDA margin of 28-30% maintained currently (Page 9).

See what Thyrocare Technologies management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes
  • Currently, Thyrocare has about ₹30 crores of debt with a three-year tenure against assets, with no bank guarantee or collateral.
  • In the immediate next 3 to 6 months, there is no plan for further debt funding as the company has enough cash.
  • Future CAPEX investments will be evaluated to decide between equity, cash, or debt, depending on the best available options.
  • The management views taking debt for healthcare equipment financing as prudent and cost-effective compared to using equity.
  • They are open to taking more term loans if needed for business CAPEX, but no firm decision has been made yet.
  • No anticipated increase in dividends reflected in future plans.

See what Thyrocare Technologies management said on order book — free account, 30 seconds.

Capex plans

Yes
  • H1 FY24 CAPEX spent: Rs. 46 crores.
  • - Rs. 16-17 crores on replacing 24 old machines.
  • - Rs. 16 crores on lab infrastructure improvements and expansions.
  • - Rs. 6 crores on LLP investments.
  • - Remaining on IT and other CAPEX.
  • H2 FY24 planned CAPEX:
  • - Rs. 5 crores to replace older machines.
  • - Rs. 5 crores on physical infrastructure and IT overhaul.
  • - Rs. 10 crores on international expansion, primarily Tanzania lab setup.
  • - Total anticipated Rs. 20 crores in H2 FY24.
  • FY25 estimated CAPEX: Around Rs. 50 crores (mainly maintenance CAPEX and expansions).
  • Capital advances of Rs. 16 crores given for other business plans.
  • Philosophy: Prefer debt financing (currently Rs. 30 crores term loan) over equity for equipment funding to optimize capital allocation.
  • Expansion focus includes Tanzania (JV incorporated) and potential future geographies in East Africa, Middle East.

Track Thyrocare Technologies — get its next earnings analysis in your feed

How does Thyrocare Technologies rank vs peers in Healthcare Services?

Pro feature
ThisThyrocare Technologies
Rev 3Mar 3

How does Thyrocare Technologies rank in Healthcare Services?

Compare Thyrocare Technologies against every Healthcare Services company (Q2 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Others in Healthcare Services this season

  • Chandan Healthca (Q2 FY27)

    Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor

  • Invicta Diagnostic (Q2 FY27)

    Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2

  • Unihealth Hosp (Q2 FY27)

    1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r

  • Sangani Hospital (Q2 FY27)

    1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →